- Home
- LPCN vs SYBX Comparison
LPCN vs SYBX Comparison
Compare LPCN & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- SYBX
- Stock Information
- Founded
- LPCN 1997
- SYBX N/A
- Country
- LPCN United States
- SYBX United States
- Employees
- LPCN N/A
- SYBX N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- SYBX Health Care
- Exchange
- LPCN Nasdaq
- SYBX Nasdaq
- Market Cap
- LPCN 16.1M
- SYBX 13.6M
- IPO Year
- LPCN N/A
- SYBX N/A
- Fundamental
- Price
- LPCN $3.17
- SYBX $1.21
- Analyst Decision
- LPCN Strong Buy
- SYBX
- Analyst Count
- LPCN 2
- SYBX 0
- Target Price
- LPCN $9.00
- SYBX N/A
- AVG Volume (30 Days)
- LPCN 71.7K
- SYBX 12.2K
- Earning Date
- LPCN 05-08-2025
- SYBX 06-17-2025
- Dividend Yield
- LPCN N/A
- SYBX N/A
- EPS Growth
- LPCN N/A
- SYBX N/A
- EPS
- LPCN N/A
- SYBX 0.21
- Revenue
- LPCN $3,674,834.00
- SYBX N/A
- Revenue This Year
- LPCN N/A
- SYBX N/A
- Revenue Next Year
- LPCN N/A
- SYBX N/A
- P/E Ratio
- LPCN N/A
- SYBX $5.82
- Revenue Growth
- LPCN N/A
- SYBX N/A
- 52 Week Low
- LPCN $2.68
- SYBX $0.90
- 52 Week High
- LPCN $11.79
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- LPCN 43.78
- SYBX 58.34
- Support Level
- LPCN $3.00
- SYBX $1.00
- Resistance Level
- LPCN $3.49
- SYBX $1.27
- Average True Range (ATR)
- LPCN 0.34
- SYBX 0.04
- MACD
- LPCN -0.05
- SYBX 0.01
- Stochastic Oscillator
- LPCN 16.50
- SYBX 69.05
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.